Lupin Limited announced Monday, September 28, that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL, filed under the 505(b)(2) pathway.
What the Product Is
Lupin's Apixaban Oral Suspension is a liquid formulation of apixaban, the active ingredient in Eliquis®, made by Bristol Myers Squibb. Apixaban is an oral anticoagulant used to prevent and treat blood clots and to reduce stroke risk in people with nonvalvular atrial fibrillation. The suspension is intended as an alternative administration option for adult patients who need anticoagulation therapy but have difficulty swallowing standard tablets.
What "Tentative Approval" Actually Means
Tentative approval is not final US marketing authorization. It typically signals that the FDA has found the application scientifically and clinically acceptable but that some regulatory condition, commonly a patent or exclusivity period tied to the reference product, still stands between the drug and commercial launch. Lupin's announcement did not disclose clinical trial results, comparative efficacy data, pharmacokinetic findings, or new safety outcomes for the suspension. The next step is final FDA approval, after which Lupin could move toward commercial availability in the US.
Where It Would Be Made
Upon receiving final approval, Lupin plans to manufacture the oral suspension at its facility in Somerset, New Jersey.
What the Company Said
Lupin CEO Vinita Gupta said: "This tentative approval reflects our continued focus on developing differentiated medicines that address meaningful patient needs. Apixaban oral suspension expands the ways in which this important therapy could be administered, while reinforcing our commitment to building a differentiated portfolio."
Why This Fits Lupin's Broader Strategy
Analysts have framed the approval as part of a deliberate shift by Lupin away from low-margin, standard generics toward more complex, value-added formulations, such as liquid suspensions of drugs that are typically sold as tablets. The move mirrors a broader pattern across the Indian pharmaceutical sector, where companies are increasingly pursuing specialized generics and complex liquid formulations to counter structural price erosion in plain solid oral medicines sold in the US market. The 505(b)(2) pathway is particularly suited to this kind of product, since apixaban already carries an established clinical and regulatory history through its approved tablet formulations, letting a company rely in part on existing safety and efficacy data for the active ingredient.
Recent Financial Context
The approval comes as Lupin reported a 16% year-over-year increase in net profit to ₹1,417 crore in its Q1 FY27 results, a backdrop that analysts say could support improved investor sentiment alongside this latest regulatory milestone.
What's Next
Lupin's announcement did not provide a timeline for when final FDA approval might come through, or when a US launch could follow. For the company's official statement, see the full press release via PR Newswire.
This article is for informational purposes only and is not medical advice. Patients should consult their doctor or pharmacist about anticoagulation therapy options.